Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $26.6 million.

  • Bioventus' Accounts Payables rose 5816.37% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.6 million, marking a year-over-year increase of 5816.37%. This contributed to the annual value of $23.7 million for FY2024, which is 283.01% up from last year.
  • As of Q3 2025, Bioventus' Accounts Payables stood at $26.6 million, which was up 5816.37% from $24.2 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' Accounts Payables ranged from a high of $41.4 million in Q3 2023 and a low of $9.9 million during Q3 2021
  • Its 5-year average for Accounts Payables is $22.2 million, with a median of $22.5 million in 2022.
  • In the last 5 years, Bioventus' Accounts Payables soared by 28251.92% in 2021 and then crashed by 4182.1% in 2024.
  • Over the past 5 years, Bioventus' Accounts Payables (Quarter) stood at $16.9 million in 2021, then skyrocketed by 116.95% to $36.7 million in 2022, then tumbled by 37.22% to $23.0 million in 2023, then increased by 2.83% to $23.7 million in 2024, then grew by 12.49% to $26.6 million in 2025.
  • Its Accounts Payables stands at $26.6 million for Q3 2025, versus $24.2 million for Q2 2025 and $19.2 million for Q1 2025.